Fig. 1

FLT3-ITD-mutated cell lines are more sensitive to Gilteritinib. a, b Western blot analysis of FLT3 in MV4-11, MOLM13, HL60 and THP1 cells. Data are shown as mean ± SD.*P < 0.05, **P < 0.01. c–f Cell viability was measured by CCK8 kit. MV4-11, MOLM13, HL60 and THP1 cells were treated with Gilteritinib (0–20 nM) for 24 h. DMSO treated cells served as a control. Data are shown as mean ± SD